Market News / Story
Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH
·
Ultragenyx entered into an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash. Under a separate NIH license, 20% of gross proceeds will be paid to NIH after closing. The sale is subject to customary closing conditions, including expiration or termination of the HSR waiting period. The transaction will monetize a non-core asset and provide immediate cash upon closing. Agreement details: Agreement type : Asset…